Researchers at Johns Hopkins Kimmel Cancer Center developed a prototype for a new cancer immunotherapy that uses engineered T cells to target a genetic alteration common among all cancers.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
